Thomas Carmichael elected to the Association of American Physicians
Dr. S. Thomas Carmichael has been elected to the Association of American Physicians, an honor society recognizing exemplary physician-scientists who contribute to clinical medicine through the pursuit of basic science. The newly elected members for 2021 were recognized at the association ’s annual meeting, which was held virtually April 8–10.Carmichael, UCLA ’s Frances Stark Professor of Neurology, is the chair of theneurology department in the David Geffen School of Medicine at UCLA and co-director of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.In his research, ...
Source: UCLA Newsroom: Health Sciences - April 9, 2021 Category: Universities & Medical Training Source Type: news

Leaking calcium in neurons an early sign of Alzheimer ’s pathology
New findings about early pathological changes in the brain may provide strategies to slow or prevent the progression of Alzheimer ’s, Yale researchers report. (Source: Yale Science and Health News)
Source: Yale Science and Health News - April 8, 2021 Category: Universities & Medical Training Source Type: news

How Infectious Diseases Affect the Brain
From a loss of taste to dementia, infectious agents cause an array of neurological symptoms. (Source: The Scientist)
Source: The Scientist - April 8, 2021 Category: Science Tags: Sponsored eBooks Source Type: news

Psychiatric and neurological problems are common in COVID-19's wake, study finds
One-third of COVID-19 survivors were diagnosed with a psychiatric or neurological condition within six months of being infected with the coronavirus. (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - April 8, 2021 Category: Science Authors: Melissa Healy Source Type: news

Risk to anaesthetists from chemical linked to Parkinson ’s disease | Letter
Trichloroethylene was used as a general anaesthetic agent, and chronic exposure over a career could have led to Parkinson ’sWe have received reports that anaesthetists exposed to trichloroethylene (TCE) may develop Parkinson ’s disease (Rates of Parkinson ’s disease are exploding. A common chemical may be to blame, 7 April). TCE was used as a general anaesthetic agent from the 1940s to the early 80s (when it was known by its tradename Trilene). If so, the presumption is that it would be chronic exposure over the course of a career that would present the greatest risk, and there has been no suggestion that...
Source: Guardian Unlimited Science - April 8, 2021 Category: Science Authors: Letters Tags: Parkinson's disease Health Medical research Science Society Doctors Neuroscience Source Type: news

New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
             Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Roche neuroscience portfolio across six therapeutic areas, including EVRYSDI ™ (risdiplam) for spinal muscular atrophy (SMA), OCREVUS® (ocrelizumab) in relapsing and primary progre...
Source: Roche Investor Update - April 8, 2021 Category: Pharmaceuticals Source Type: news

New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
             Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Roche neuroscience portfolio across six therapeutic areas, including EVRYSDI ™ (risdiplam) for spinal muscular atrophy (SMA), OCREVUS® (ocrelizumab) in relapsing and primary progre...
Source: Roche Media News - April 8, 2021 Category: Pharmaceuticals Source Type: news

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH ...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

One in three survivors of severe Covid diagnosed with mental health condition
Study finds 34% developed psychiatric or neurological conditions after six monthsCoronavirus – latest updatesSee all our coronavirus coverageOne in three people who were severely ill with coronavirus were subsequently diagnosed with a neurological or psychiatric condition within six months of infection, a study has found.The observational research, which is the largest of its kind, used electronic health records of 236,379 patients mostly from the US and found 34% experienced mental health and neurological conditions afterwards. The most common being anxiety, with 17% of people developing this.Continue reading... (So...
Source: Guardian Unlimited Science - April 7, 2021 Category: Science Authors: Sarah Marsh Tags: Coronavirus Mental health Science Infectious diseases Medical research Society World news UK news US news Source Type: news

New Real-World Observational Analysis of UPTRAVI ® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients
SOUTH SAN FRANCISCO, CA – April 6, 2021 – Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found more than three-quarters (76%) of pulmonary arterial hypertension (PAH) patients treated with UPTRAVI® (selexipag) either maintained (56%) or reduced (20%) their one-year mortality risk score. The SPHERE results were published in the April issue of the Journal of Heart and Lung Transplantation (JHLT). SPHERE is an ongoing real-world, observational, user registry using two different risk assessment methods that describes the clinical characte...
Source: Johnson and Johnson - April 6, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What are thoughts? Where do they come from – and where do they go?
The long-running series in which readers answer other readers ’ questions on subjects ranging from trivial flights of fancy to profound scientific and philosophical conceptsWhat are thoughts? Where do they come from, and where do they go when they disappear? Are they “filed” somewhere, a bit like memories, where we can find them again, or once a thought has gone is that it?Sue Christian, OswestryPost your answers (and new questions) below or send them tonq@theguardian.com. A selection will be published on Sunday.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 6, 2021 Category: Science Tags: Life and style Psychology Neuroscience Source Type: news

Inside Ibogaine, One of the Most Promising and Perilous Psychedelics for Addiction
Amber Capone had become afraid of her husband. The “laid-back, bigger than life and cooler than cool” man she’d married had become isolated, disconnected and despondent during his 13 years as a U.S. Navy SEAL. Typically, he was gone 300 days of the year, but when he was home, Amber and their two children walked on eggshells around him. “Everyone was just playing nice until he left again,” Amber says. In 2013, Marcus retired from the military. But life as a civilian only made his depression, anger, headaches, anxiety, alcoholism, impulsivity and violent dreams worse. Sometimes he’d get up...
Source: TIME: Health - April 5, 2021 Category: Consumer Health News Authors: Mandy Oaklander Tags: Uncategorized Drugs feature Magazine Mental Health Source Type: news

Ashok Soota launches not-for-profit entity for medical research, commits Rs 200 crore
SKAN ’s research for the projects would be done in-house and through partners and the Centre for Brain Research (CBR) at Indian Institute Science, Bangalore (IISc) is the strategic partner for Neurological research, said the organisation in a press release. (Source: The Economic Times)
Source: The Economic Times - April 4, 2021 Category: Consumer Health News Source Type: news

Empathy, compassion, personality, attitudes: can people change?
There is plenty of evidence that empathy can be taught in childhood, but it gets more complicated when it comes to adults, especially when it is forcedCan people change?That ’s the question behind the multibillion-dollarself-help industry, the proliferation of blogs and podcasts that promise to make you a better human, and the ubiquitous and vacuous “inspo” memes.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 3, 2021 Category: Science Authors: Tory Shepherd Tags: Health & wellbeing Psychology Neuroscience Mental health Source Type: news

Anesthesia Impairs Memory in Mice
A study that compared several anesthetic regimens in rodents showed that only one--inhaled isoflurane--wasn't detrimental to the activity of neurons in the hippocampus. (Source: The Scientist)
Source: The Scientist - April 1, 2021 Category: Science Tags: News & Opinion Source Type: news

Multilingual people have an advantage over those fluent in only two languages
(University of Tokyo) Multilingual people have trained their brains to learn languages, making it easier to acquire more new languages after mastering a second or third. In addition to demystifying the seemingly herculean genius of multilinguals, researchers say these results provide some of the first neuroscientific evidence that language skills are additive, a theory known as the cumulative?enhancement model of language acquisition. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 1, 2021 Category: International Medicine & Public Health Source Type: news

How brain cells repair their DNA reveals " hot spots " of aging and disease
(Salk Institute) Neurons lack the ability to replicate their DNA, so they're constantly working to repair damage to their genome. A new study by Salk scientists finds that these repairs are not random, but instead focus on protecting certain genetic " hot spots " that appear to play a critical role in neural identity and function. The findings published in the April 2, 2021, issue of Science. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 1, 2021 Category: International Medicine & Public Health Source Type: news

Mary Jeanne Kreek, Methadone Developer, Dies at 84
A physician and neurobiologist at the Rockefeller University who specialized in addiction research, Kreek was best known for her work on developing the treatment for heroin addiction. (Source: The Scientist)
Source: The Scientist - March 31, 2021 Category: Science Tags: News & Opinion Source Type: news

The Scientist Speaks Ep. 16 - At the Breaking Point: Mitochondrial Deletions and the Brain
Researchers characterize large mitochondrial deletions to understand their implications in neurological disorders. (Source: The Scientist)
Source: The Scientist - March 31, 2021 Category: Science Tags: Podcasts Source Type: news

Mystery brain disorder baffles Canadian doctors
Spasms, memory loss and hallucinations among symptoms of 43 patients in Acadian region of New Brunswick provinceDoctors in Canada are concerned they could be dealing with a previously unknown brain disease amid a string of cases involving memory loss, hallucinations and muscle atrophy.Politicians in the province of New Brunswick have demanded answers, but with so few cases, experts say there are far more questions than answers and have urged the public not to panic.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 30, 2021 Category: Science Authors: Leyland Cecco in Toronto Tags: Canada Neuroscience World news Medical research Americas Health Source Type: news

Mystery brain disorder baffles Canadian medicine
Spasms, memory loss and hallucinations among symptoms of 43 patients in Acadian region of New Brunswick provinceDoctors in Canada are concerned they could be dealing with a previously unknown brain disease amid a string of cases involving memory loss, hallucinations and muscle atrophy.Politicians in the province of New Brunswick have demanded answers, but with so few cases, experts say there are far more questions than answers and have urged the public not to panic.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 30, 2021 Category: Science Authors: Leyland Cecco in Toronto Tags: Canada Neuroscience World news Medical research Americas Health Source Type: news

Researcher strives to increase participation of neurodiverse students in STEM fields
(Northern Arizona University) Through a project NAU psychologist Ronda Jenson is leading, a team of researchers from The Ohio State University, Auburn University, the University of Missouri--Kansas City, the University of Hawaii and Kansas State University, are creating a strategic plan to support the success of neurodivergent students in higher education leading to STEM careers. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 30, 2021 Category: International Medicine & Public Health Source Type: news

Early Training Forestalls Motor, Memory Difficulties in Mouse Model of Rett Syndrome
Manipulating the activity of neurons active during training had similar effects on the mice's behavior. (Source: The Scientist)
Source: The Scientist - March 29, 2021 Category: Science Tags: News & Opinion Source Type: news

Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, NJ (March 29, 2021) - Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to make available up to 220 million doses of its single-shot COVID-19 vaccine candidate to African Union’s 55 member states with delivery beginning in the third quarter of 2021. AVAT also has the potential to order an additional 180 million doses, for a combined total of up to 400 million doses through 2022. The availability of the vaccine candidate is subject to its successful appr...
Source: Johnson and Johnson - March 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Receives Positive CHMP Opinion for PONVORY ™ (ponesimod) for the Treatment of Adults With Relapsing Forms of Multiple Sclerosis With Active Disease Defined by Clinical or Imaging Features
BEERSE, BELGIUM, MARCH 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for PONVORY™ (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease defined by clinical or imaging features.[3]“Relapsing forms of multiple sclerosis (MS) have varied and often unpredictable symptoms, posing a unique human, societal and economic burden,” said Catherine T...
Source: Johnson and Johnson - March 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bald Eagle Killer Identified
After a nearly 30-year hunt, researchers have shown that a neurotoxin generated by cyanobacteria on invasive plants is responsible for eagle and waterbird deaths from vacuolar myelinopathy. (Source: The Scientist)
Source: The Scientist - March 25, 2021 Category: Science Tags: News & Opinion Source Type: news

Seven new projects to start on EBRAINS research infrastructure, joining the HBP community
(Human Brain Project) Seven innovative projects will soon start on the EBRAINS research infrastructure, becoming members of the HBP community. The selected projects range from Neuroscience to Medicine, AI and Robotics, with successful applicants coming from science and industry in Italy, Spain, Germany, Switzerland and the Netherlands. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 25, 2021 Category: International Medicine & Public Health Source Type: news

Massive study reveals few differences between men and women's brains
(Rosalind Franklin University of Medicine and Science) How different are men and women's brains? The question has been explored for decades, but a new study led by Rosalind Franklin University neuroscientist Lise Eliot is the first to coalesce this wide-ranging research into a single mega-synthesis. And the answer is: hardly at all. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 25, 2021 Category: International Medicine & Public Health Source Type: news

Flexible Synapse Strength May Underpin Mammal Brain's Complexity
Neural connections in the mouse neocortex can release multiple packages of neurotransmitters per electrical impulse, a study finds. (Source: The Scientist)
Source: The Scientist - March 24, 2021 Category: Science Tags: The Literature Magazine Issue Source Type: news

Infographic: A New Model of Synapse Strength
Synapses in the mouse neocortex can release multiple packages of neurotransmitters, suggesting that connection strength is more flexible than previously thought. (Source: The Scientist)
Source: The Scientist - March 24, 2021 Category: Science Tags: Infographics Magazine Issue Source Type: news

Scientists discover why humans have such big brains
Molecular switch makes human organ three times larger than great apes ’, study findsIt is one of the defining attributes of being human: when compared with our closest primate relatives, we have incredibly large brains.Now scientists have shed light on the reasons for the difference, by collecting cells from humans, chimps and gorillas and turning them into lumps of brain in the laboratory.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 24, 2021 Category: Science Authors: Ian Sample Science editor Tags: Science Neuroscience Stem cells UK news Source Type: news

These Moms Work as Doctors and Scientists. But They ’ve Also Taken On Another Job: Fighting COVID-19 Misinformation Online
Last March, friends and neighbors began stopping Emily Smith in her town outside of Waco, Texas, with questions about the coronavirus. An epidemiologist at Baylor University, Smith knows all too well how viruses are transmitted. But as the wife of a pastor and as a woman of faith, she also holds a trusted position in her community, and she would speak to those who asked about why she personally thought social distancing was a moral choice. As the weeks wore on, the questions kept coming: “What does flatten the curve mean?” “Is it safe for my child to kick a soccer ball outside with a friend?” So she...
Source: TIME: Health - March 24, 2021 Category: Consumer Health News Authors: Eliana Dockterman Tags: Uncategorized feature Magazine Misinformation & Disinformation Source Type: news

This High School Student Invented An Eye-Tracking Test To Detect Brain Disorders
Alay Shah of Plano West Senior High School, Plano, TX, designed AI algorithms to detect eye movement differences in people with various neurological conditions. The invention earned him seventh place at the 2021 Regeneron Science Talent Search. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 23, 2021 Category: Pharmaceuticals Authors: Caroline Seydel, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

Cochrane International Mobility - Vanessa Young
Cochrane is made up of  11,000 members and over 67,000 supporters come from more than 130 countries, worldwide. Our volunteers and contributors are researchers, health professionals, patients, carers, people passionate about improving health outcomes for everyone, everywhere.Getting involved in Cochrane ’s work means becoming part of a global community. TheCochrane International Mobility programme connects successful applicants with a placement in a host Cochrane Group, learning more about the production, use, and knowledge translation of Cochrane reviews. The prgramme offers opportunities fo...
Source: Cochrane News and Events - March 22, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news

UK to test existing drugs as treatment for MS in world-first trial
Researchers will test several drugs at once to speed up identification of those that slow or reverse symptomsDoctors in the UK are to launch a world-first clinical trial to assess whether drugs already on the market can prevent multiple sclerosis (MS) from worsening over time and even reverse the disabilities it causes.The groundbreaking Octopus trial, so named because of its various arms, will allow researchers to investigate the potential benefits of several drugs at once, in the hope of identifying effective new treatments three times faster than if the medicines were trialled separately.Continue reading... (Source: Gua...
Source: Guardian Unlimited Science - March 22, 2021 Category: Science Authors: Ian Sample Science editor Tags: Multiple sclerosis Science Neuroscience Medical research Society UK news Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Happiness can be learned
In this study, researchers demonstrated the effectiveness of an integrated mental training program in which the participants on the one hand practiced meditation exercises and, on the other, explored topics related to philosophy, psychology and neuroscience in depth. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 19, 2021 Category: International Medicine & Public Health Source Type: news

Scientists identify genetic pathway that suppresses Lou Gehrig's Disease
(Ulsan National Institute of Science and Technology(UNIST)) South Korea's Ulsan National Institute of Science and Technology (UNIST) has unveiled a neuroprotective pathway that suppresses Lou Gehrig's Disease (ALS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 19, 2021 Category: International Medicine & Public Health Source Type: news

Sex of Human Cells Matters in Studying Neurological Disease
Authors of a new review urge researchers to consider how the chromosomal sex of a cell affects experiments in research on neurodegeneration. (Source: The Scientist)
Source: The Scientist - March 18, 2021 Category: Science Tags: News & Opinion Source Type: news

The shape of things to come: Shifting rewards are encoded using special neuronal patterns
(University of Tsukuba) Researchers from the University of Tsukuba have found that that during the processing of rewards that change in value over time, dopamine neurons exhibit a pattern of neuronal activity that is distinct from previously established neuronal firing related to reward prediction. This work opens the door for future research regarding the way in which rewards are processed, and more broadly, the way that dopamine neurons process information in real-time. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 18, 2021 Category: International Medicine & Public Health Source Type: news

New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New two-year data show Roche ’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)
Basel, 16 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new exploratory 2-year longer-term data from Part 2 of SUNFISH, a global placebo-controlled study evaluating Evrysdi ™ (risdiplam) in people aged 2-25 years with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA). The study suggests that gains in motor function observed with Evrysdi treatment at month 12 continued to improve or were maintained at month 24 across primary and secondary endpoint measures. Based on the natural history of the disease, people with Types 2 and 3 SMA who remain untreated decline in motor function over time. Th...
Source: Roche Media News - March 16, 2021 Category: Pharmaceuticals Source Type: news

New two-year data show Roche ’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)
Basel, 16 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new exploratory 2-year longer-term data from Part 2 of SUNFISH, a global placebo-controlled study evaluating Evrysdi ™ (risdiplam) in people aged 2-25 years with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA). The study suggests that gains in motor function observed with Evrysdi treatment at month 12 continued to improve or were maintained at month 24 across primary and secondary endpoint measures. Based on the natural history of the disease, people with Types 2 and 3 SMA who remain untreated decline in motor function over time. Th...
Source: Roche Investor Update - March 16, 2021 Category: Pharmaceuticals Source Type: news

‘The ketamine blew my mind’: can psychedelics cure addiction and depression?
This week sees the opening of the first UK high-street clinic offering psychedelic-assisted therapy. Could popping psilocybin be the future of mental healthcare?In the summer of 1981, when he was 13, Grant crashed a trail motorbike into a wall at his parents ’ house in Cambridgeshire. He’d been hiding it in the shed, but “it was far too powerful for me, and on my very first time starting it in the garden, I smashed it into a wall”. His mother came outside to find the skinny teenager in a heap next to the crumpled motorbike. “I was in a lot of trouble.”Grant hadn ’t given this child...
Source: Guardian Unlimited Science - March 13, 2021 Category: Science Authors: Words: Alexandra Jones Illustration: Frieda Ruh Tags: Health & wellbeing Mental health Depression Alcoholism Drugs NHS Society Neuroscience Psychology Life and style Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
NEW BRUNSWICK, N.J., March 12, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percent reduction in symptomatic COVID-19 disease in participants who received the vaccine in comparison to participants give...
Source: Johnson and Johnson - March 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Commission (EC) has granted a Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. The CMA follows a Positive Opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).2 The CMA is valid in all 27 member states of the European Union (EU), plus Norway, Iceland and Liechtenstei...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion to recommend the Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percen...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Singapore scientists develop novel gene editor to correct disease-causing mutations
(Agency for Science, Technology and Research (A*STAR), Singapore) The Genome Institute of Singapore (GIS) has developed a CRISPR-based gene editor to correct mutations that cause genetic disorders. The C-to-G Base Editor (CGBE) by GIS advances the widely adopted CRISPR-Cas9 technology to enable molecular surgery on the human genome. This invention opens up treatment options for approximately 40 per cent of single-base substitutions associated with human diseases - including cystic fibrosis, cardiovascular diseases, musculoskeletal diseases, and neurological disorders. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 11, 2021 Category: Biology Source Type: news

Brain activity data may improve stock market forecasts, study shows
US research suggests scans offer better price predictions than the actual choices investors makeFrom never trading during the first 30 minutes, to not returning to a stock for a third time, financial investors have a stack of superstitions for predicting stock price changes. Now neuroscientists may have hit upon a more accurate prediction tool: scans of people ’s brain activity just before they make investment choices.Astudy in the Journal of Neuroscience suggests brain activity may be a better predictor of stock price changes than prior market trends, or the actual stocks people decide to invest in.Continue reading....
Source: Guardian Unlimited Science - March 8, 2021 Category: Science Authors: Linda Geddes Tags: Neuroscience Stock markets Investing US news Source Type: news

Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
CORK, IRELAND, March 6, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented positive long-term data from the global Phase 3b trial of the first complete, long-acting (LA), two-drug injectable regimen (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The 96-week findings of the Antiretroviral Therapy as Long-Acting Suppression Every 2 Months (ATLAS-2M) trial confirmed the primary endpoint, met at Week 48, and met the secondary endpoint, showing efficacy of both month...
Source: Johnson and Johnson - March 6, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news